Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial

Atrial Fibrillation

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Heart Rhythm

Boriani G, McIntyre WF, Ramasundarahettige C, Proietti M, Glotzer TV, Diemberger I, Nielsen JC, Essebag V, Granger CB, Sandhu RK, Benezet-Mazuecos J, Mabo P, Coutu B, Wong JA, Gold MR, Lopes RD, Healey JS, ARTESiA Investigators

doi: 10.1016/j.hrthm.2025.07.002

Atrial FibrillationThrombosis and Stroke

Left Atrial Appendage Closure versus Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Long-Term Outcomes from Four Randomized Trials

Heart Rhythm

Kaisaier W, Xu Z, Guo L, Dong Y, Chen Y, Lip GYH, Zhu W

doi: 10.1016/j.hrthm.2025.07.051

Heart, Artery and Coronary Diseases

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

Am Heart J

Steg PG, Nicolas J, Baber U, Sartori S, Zhang Z, Feng Y, Angiolillo DJ, Briguori C, Cohen DJ, Collier T, Dangas G, Dudek D, Escaned J, Gibson CM, Han YL, Huber K, Kastrati A, Kaul U, Marx SO, Kornowski R, Kunadian V, Vogel B, Oliva A, Mehta SR, Moliterno D, Sardella G, Krucoff M, Shlofmitz RA, Sharma S, Pocock S, Mehran R

doi: 10.1016/j.ahj.2025.01.016

Atrial Fibrillation

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

J Am Coll Cardiol

Galea R, De Marco F, Aminian A, Meneveau N, Chalkou K, Anselme F, Gräni C, Franzone A, Vranckx P, Fischer U, Valgimigli M, Räber L

doi: 10.1016/j.jacc.2025.03.535

Atrial Fibrillation

Inverse association between remnant cholesterol and risks of atrial fibrillation among patients with type 2 diabetes

Front Endocrinol (Lausanne)

Jiang Z, Zhao K, Sun M, Sun J, Pan S

doi: 10.3389/fendo.2025.1461613

Atrial FibrillationThrombosis and Stroke

Association of Rate-Control and Antiarrhythmic Medication Use and Risk of Ischemic Stroke and Death in Patients on Dialysis With Atrial Fibrillation

J Am Heart Assoc

Lidgard B, Fan DX, Zelnick LR, An J, Harrison TN, Lee MS, Singer D, Tabada GH, Go AS, Bansal N

doi: 10.1161/JAHA.124.038511

Atrial FibrillationThrombosis and Stroke

Prevalence and Factors Associated With Atrial Fibrillation Among Young Patients With Ischemic Stroke

J Am Heart Assoc

van Kempen EJ, Schellekens MMI, Verhoeven JI, Ekker MS, Verburgt E, Immens MHM, Hilkens NA, Boot EM, van Alebeek ME, Brouwers PJAM, Arntz RM, van Dijk GW, Gons RAR, van Uden IWM, den Heijer T, van Tuijl JH, de Laat KF, van Norden AGW, Vermeer SE, van Zagten MSG, van Oostenbrugge RJ, Wermer MJH, Nederkoorn PJ, van Rooij FG, van den Wijngaard IR, de Leeuw FE, Ten Cate TJF, Tuladhar AM

doi: 10.1161/JAHA.125.043996

Atrial FibrillationTherapy and Intervention

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

JAMA Cardiol

Patel SM, Giugliano RP, Morrow DA, Goodrich EL, Murphy SA, Hug B, Parkar S, Chen SA, Goodman SG, Joung B, Kiss RG, Wojakowski W, Weitz JI, Bloomfield D, Sabatine MS, Ruff CT

doi: 10.1001/jamacardio.2025.3393

Atrial Fibrillation

Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis

Eur Heart J

Raveendra K, Nadarajah R, Larvin H, Farooq M, Haris M, Cutting U, Kang J, Wilkinson C, Dalakoti M, Kotecha D, Lip GYH, Boriani G, Camm AJ, Van Gelder IC, Wu J, Gale CP

doi: 10.1093/eurheartj/ehag021

Related content

Atrial Fibrillation Progression in Patients with Device-Detected Subclinical Atrial Fibrillation: Insights from the ARTESiA Trial

Left Atrial Appendage Closure versus Oral Anticoagulation for Stroke Prevention in Atrial Fibrillation: Long-Term Outcomes from Four Randomized Trials

Characterizing High-Risk Enrollment Criteria and Impact on Clinical Outcomes in a Large Randomized Clinical Trial: Insights From the TWILIGHT Trial

3-Year Clinical Outcomes Comparing the Amulet vs Watchman FLX for Left Atrial Appendage Closure in Patients With Atrial Fibrillation: Results From the SWISS-APERO Randomized Clinical Trial

Inverse association between remnant cholesterol and risks of atrial fibrillation among patients with type 2 diabetes

Association of Rate-Control and Antiarrhythmic Medication Use and Risk of Ischemic Stroke and Death in Patients on Dialysis With Atrial Fibrillation

Prevalence and Factors Associated With Atrial Fibrillation Among Young Patients With Ischemic Stroke

Safety of Factor XI Inhibition With Abelacimab in Atrial Fibrillation by Kidney Function: A Prespecified Analysis of the AZALEA-TIMI 71 Randomized Clinical Trial

Non-antiarrhythmic pharmacotherapy in cardio-renal-metabolic disease and incident atrial fibrillation: a trial meta-analysis